Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

SoliPharma of Hangzhou Raises $36.5 Million to Develop High End Generics

publication date: Sep 11, 2019

SoliPharma, a Hangzhou company, completed a $36.5 million financing to support its development of high-end, difficult-to-make generic drugs. The company, founded in 2010, develops products with partners, and registers them in China and the US, with an eye toward global markets over time. Its expertise ranges from early API development, through product development and into regulatory approval. The company's SoliTech® Solutions division has been given the mission of “bringing challenging molecules to global markets” more quickly. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China